FDA approves XFG-adapted COVID-19 vaccine
The 2026 to 2027 formulation aligns with FDA guidance on the preferred composition for COVID-19 vaccines beginning this fall.
-
By
-
Kathryn Wighton
-
August 28, 2026
-
Clinical Scorecard: FDA approves XFG-adapted COVID-19 vaccine
At a Glance
| Category | Detail |
|---|
| Condition | COVID-19 |
| Key Mechanisms | XFG-adapted vaccine targeting SARS-CoV-2 variants |
| Target Population | Adults aged 65 years and older and patients aged 5 through 64 years with at least 1 underlying condition |
| Care Setting | Pharmacies, hospitals, and clinics |
Key Highlights
- FDA approved XFG-adapted COMIRNATY vaccine for high-risk populations
- Vaccine targets the XFG variant and other circulating variants
- Over 5 billion doses of COMIRNATY have been distributed globally
- Vaccination may not protect all recipients, especially immunocompromised individuals
- Severe allergic reactions and myocarditis reported as potential adverse events
Guideline-Based Recommendations
Diagnosis
Management
- Avoid administration in patients with a history of severe allergic reactions to COMIRNATY or its components
Monitoring & Follow-up
- Monitor for adverse events such as injection-site reactions, fatigue, and myocarditis
Risks
- Remote chance of severe allergic reactions
- Myocarditis and pericarditis most common in males aged 12-24 years
Patient & Prescribing Data
Adults aged 65 years and older and patients aged 5 through 64 years with underlying conditions
Immunocompromised patients may have reduced immune response
Clinical Best Practices
- Ensure patients are informed about potential adverse events
- Monitor patients post-vaccination for any immediate allergic reactions
Related Resources & Content
